PET/CT in patients with hepatocellular carcinoma using [18F]fluorocholine: preliminary comparison with [18F]FDG PET/CT

PurposeThe diagnostic accuracy of [18F]fluorodeoxyglucose (FDG) PET is insufficient to characterise hepatocellular carcinoma (HCC) in liver masses and to diagnose all cases of recurrent HCC. HCC has been reported to take up [11C]acetate, but routine use of this tracer is difficult. Choline is another tracer of lipid metabolism, present in large amounts in HCC. In a proof-of-concept study, we evaluated [18F]fluorocholine (FCH) uptake by HCC and compared FCH PET/CT with FDG PET/CT.MethodsTwelve patients with newly diagnosed (n=8) or recurrent HCC (n=4) were prospectively enrolled. HCC was assessed by histology in eight cases and by American Association for the Study of Liver Diseases (AASLD) criteria in four cases. All patients underwent whole-body PET/CT 10 min after injection of 4 MBq/kg FCH. Within 1 week, 9 of the 12 patients also underwent whole-body FDG PET/CT 1 h after injection of 5 MBq/kg FDG.ResultsThe per-patient analysis showed a detection rate of 12/12 using FCH PET/CT for both newly diagnosed and recurrent HCC. The median signal to noise ratio was 1.5±0.38. There was a trend towards a higher FCH SUVmax in well-differentiated HCC (15.6±7.9 vs 11.9±0.9, NS). Of the nine patients who underwent FCH and FDG PET/CT, all nine were positive with FCH whereas only five were positive with FDG.ConclusionFCH provides a high detection rate for HCC, making it potentially useful in the initial evaluation of HCC or in the detection of recurrent disease. The favourable result of this proof-of-concept study opens the way to a phase III prospective study.

[1]  Chi-Lai Ho,et al.  11C-acetate PET imaging in hepatocellular carcinoma and other liver masses. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  V. Mazzaferro,et al.  Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. , 1996, The New England journal of medicine.

[3]  M J Welch,et al.  Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. , 2001, Nuclear medicine and biology.

[4]  R. Coleman,et al.  Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. , 2001, Cancer research.

[5]  M P Sandler,et al.  Evaluation of benign vs malignant hepatic lesions with positron emission tomography. , 1998, Archives of surgery.

[6]  H D Humes,et al.  Carbon-11-acetate PET imaging in renal disease. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  J. Bruix,et al.  Management of hepatocellular carcinoma , 2005, Hepatology.

[8]  M. Coel,et al.  Prostate cancer localization with 18fluorine fluorocholine positron emission tomography. , 2005, The Journal of urology.

[9]  S. Zeuzem,et al.  Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma , 1999, American Journal of Gastroenterology.

[10]  G. V. von Schulthess,et al.  Fluorocholine PET/CT in patients with prostate cancer: initial experience. , 2005, Radiology.

[11]  J. Ruíz-Cabello,et al.  Phospholipid metabolites as indicators of cancer cell function , 1992, NMR in biomedicine.

[12]  M. Ozaki,et al.  Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  M. Laeeq Khan,et al.  Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. , 2000, Journal of hepatology.

[14]  C. Zornig,et al.  Impact of Staging on the Treatment of Hepatocellular Carcinoma , 1993, Endoscopy.

[15]  T. Hara 18F-fluorocholine: a new oncologic PET tracer. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  P. Shreve,et al.  Imaging of the pancreas and related diseases with PET carbon-11-acetate. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  G. Liu,et al.  Quantification of choline compounds in human hepatic tumors by proton MR spectroscopy at 3 T , 2005, Magnetic resonance in medicine.